Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 4 (2007), Issue 7 (July)

1. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.
   Biomed Chromatogr, 21(7): 747-54. [Abstract] [Full-text]
2. Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.
   Oncologist, 12(6): 719-26. [Abstract] [Full-text]
3. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
   Blood, 110(2): 727-34. [Abstract] [Full-text]
4. Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
   Blood, 110(2): 678-85. [Abstract] [Full-text]
5. Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells.
   Blood, 110(2): 651-60. [Abstract] [Full-text]
6. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
   Clin Exp Med, 7(2): 47-55. [Abstract] [Full-text]
7. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
   Stem Cells Dev, 16(3): 503-14. [Abstract] [Full-text]
8. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability.
   Br J Haematol, 138(3): 369-73. [Abstract] [Full-text]
9. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
   J Neurooncol, 84(1): 103-5. [Abstract] [Full-text]
10. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
    Cancer, 110(2): 340-4. [Abstract] [Full-text]
11. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
    Cancer, 110(2): 309-17. [Abstract] [Full-text]
12. Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation.
    Am J Hematol, 82(8): 758-60. [Abstract] [Full-text]
13. Neoadjuvant imatinib in a locally advanced gastrointestinal stromal tumour (GIST) of the rectum: a rare case of two GISTs within a family without a familial GIST syndrome.
    Eur J Gastroenterol Hepatol, 19(8): 711-3. [Abstract] [Full-text]
14. The challenge of opportunities: how far can and should we go with targeted treatments and modern diagnostics in gastrointestinal stromal tumors?
    Eur J Gastroenterol Hepatol, 19(8): 619-22. [Abstract] [Full-text]
15. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
    J Pathol, 212(4): 402-10. [Abstract] [Full-text]
16. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
    Int J Gynecol Cancer, 17(4): 784-8. [Abstract] [Full-text]
17. Vaginal tumors with histologic and immunocytochemical feature of gastrointestinal stromal tumor: two cases and review of the literature.
    Int J Gynecol Cancer, 17(4): 928-33. [Abstract] [Full-text]
18. Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs).
    J Cancer Res Clin Oncol, 133(9): 589-97. [Abstract] [Full-text]
19. Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
    Cancer Chemother Pharmacol, 60(4): 581-7. [Abstract] [Full-text]
20. BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
    Cancer Res, 67(14): 7045-53. [Abstract] [Full-text]
21. Current Treatment Options: Impact of Cytogenetics on the Course of Myelodysplasia.
    Curr Treat Options Oncol. [Abstract] [Full-text]
22. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Clin Cancer Res, 13(14): 4280-90. [Abstract] [Full-text]
23. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
    Clin Cancer Res, 13(14): 4164-9. [Abstract] [Full-text]
24. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Eur J Haematol, 79(2): 170-3. [Abstract] [Full-text]
25. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
    Lab Invest, 87(8): 767-79. [Abstract] [Full-text]
26. The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
    Leukemia, 21(8): 1708-14. [Abstract] [Full-text]
27. Effect of FLT3 Inhibition on Normal Hematopoietic Progenitor Cells.
    Ann N Y Acad Sci, 1106: 190-6. [Abstract] [Full-text]
28. Primary omental Gastrointestinal stromal tumor (GIST).
    World J Surg Oncol, 5: 66. [Abstract] [Full-text]
29. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma.
    Eur J Endocrinol, 157(2): 215-20. [Abstract] [Full-text]
30. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Cancer Genet Cytogenet, 176(2): 166-8. [Abstract] [Full-text]
31. Involvement of tyrosine kinase signaling in maintaining murine embryonic stem cell functionality.
    Exp Hematol, 35(8): 1293-302. [Abstract] [Full-text]
32. Modulation of T-effector function by imatinib at the level of cytokine secretion.
    Exp Hematol, 35(8): 1266-71. [Abstract] [Full-text]
33. Chronic myeloid leukaemia.
    Lancet, 370(9584): 342-50. [Abstract] [Full-text]
34. New strategies for treating GIST when imatinib fails.
    Cancer Invest, 25(5): 328-35. [Abstract] [Full-text]
35. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
    Breast Cancer Res, 9(4): R45. [Abstract] [Full-text]
36. Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience.
    Pediatr Transplant, 11(6): 645-9. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.